Pharmaceutical compositions for inhibiting absorption of cholesterol

• US 3,954,976 A
• Filed: 12/14/1973
• Issued: 05/04/1976
• Est. Priority Date: 12/14/1973
• Status: Expired due to Term

• Current Assignee: The Procter & Gamble Company
• Original Assignee: The Procter & Gamble Company
• Inventors: Mattson, Fred Hugh, Volpenhein, Robert Anthony
• Primary Examiner(s): Roberts, Elbert L.
• Application Number:
  US05/425,010
• Time in Patent Office: 872 Days
• Field of Search: 424/180
• US Class Current: 514/23
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: C07H 13/06 Fatty acids

Abstract

Pharmaceutical compositions for inhibiting the absorption of cholesterol comprising effective unit dosage amounts of a polyol fatty acid ester having at least four fatty acid ester groups; and a method for treating and/or preventing hypercholesterolemia in an animal comprising systematically administering to such animal successive therapeutically effective doses of said polyol fatty acid ester.

Claims

1. A pharmaceutical composition in effective unit dosage amounts for inhibiting the absorption of cholesterol comprising from about 0.1 gram to about 5 grams of a polyol fatty acid ester having at least four fatty acid esters groups, wherein the polyol is selected from the group consisting of sugars and sugar alcohols containing from four to eight hydroxyl groups and wherein each fatty acid group has from about eight to about 22 carbon atoms.

2. A composition in accordance with claim 1 wherein the hydroxy groups of the polyol are all esterified.

3. A composition in accordance with claim 1 containing from about 0.5 gram to about 2 grams per unit dosage.

5. A method for treating hypercholesterolemia by inhibiting the absorption of cholesterol comprising systemically administering to an animal susceptible to or afflicted with hypercholesterolemia successive therapeutically effective doses of a polyol fatty acid ester having at least 4 fatty acid esters groups, wherein the polyol is selected from the group consisting of sugars and sugar alcohols containing from four to eight hydroxyl groups and wherein each fatty acid group has from about eight to about 22 carbon atoms.

4. A composition in accordance with claim 5 wherein the esterified polyol is sucrose octaoleate.

6. The method of claim 5 wherein the hydroxy groups of the polyol are all esterified.

7. The method of claim 6 wherein the doses are unit doses containing from about 0.5 gram to about 5 grams per unit dose.

8. The method of claim 7 wherein the unit doses are from about 0.5 to 2 grams per unit dose.

9. The method of claim 8 wherein the esterified polyol is sucrose octaoleate.